Themis Medicare has received approval for its immunomodulatory antiviral drug VIRALEX (Generic name: Inosine Pranobex) for treatment of COVID-19, from Drug Controller General of India (DCGI).
The drug regulatory authority granted permission to manufacture and market this new drug for restricted emergency use as add on therapy for treatment of mild and moderate COVID-19, under NDCT Rules 2019 based on evaluation in consultation with the Subject Expert Committee (SEC) as part of accelerated approval process considering the emergency situation and unmet medical need in light of COVID-19 outbreak in the country. VIRALEX would be available on prescription.
Themis Medicare is a research-based pharmaceutical company specializing in manufacture of a wide range of products for application areas like Pain Management, Critical Care and Anti-Infectives.
